Ractigen doses first subject in Phase I ALS treatment trial
Ractigen Therapeutics has dosed the first subject in the randomised Phase I clinical trial of its small interfering RNA (siRNA) …
Post
-
-
XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases …
-
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
California company Arrowhead Pharmaceuticals has announced that it has dosed the first patient as part of its new Phase I/IIa …
-
Zura Bio initiates Phase II systemic sclerosis treatment trial
Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the humanised tetravalent bispecific dual-antagonist antibody, tibulizumab, in …
-
First patient dosed as Marengo’s invikafusp alfa trial expands to Europe
Clinical-stage biotechnology company Marengo Therapeutics has announced that it has dosed the first patient in Phase II of its STARt-001 …
-
BMS sees success in Phase III Sotyktu psoriatic arthritis trials
Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and safety of …
-
JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
Japanese healthcare firm, JCR Pharmaceuticals, has announced that it has dosed the first paediatric patient as part of its Phase …
-
GSK’s combo therapy trial for advanced ovarian cancer meets primary endpoint
GSK has reported that the double-blind, randomised Phase III FIRST-ENGOT-OV44 trial of Zejula (niraparib) and Jemperli (dostarlimab) combination in treating …
-
2024: record year for AI trials
In 2024, artificial intelligence (AI) continued to be shown as an invaluable tool with the potential to accelerate clinical trials …
-
Most significant clincal trials of 2024
From gene therapies to psychedelics and cancer vaccines to HIV pre-exposure prophylaxis (PrEP) drugs, 2024 has been a busy year …
-
First blood-stage malaria vaccine ‘a much-needed addition’ – analyst
The RH5.1/Matrix-M blood-stage vaccine could constitute a crucial secondary defence for communities at high risk of malaria infection, including those …
-
Alumis reports positive outcomes from Phase I trial of TYK2 inhibitor
Alumis has revealed encouraging results from a Phase I clinical trial of a selective tyrosine kinase 2 (TYK2) inhibitor, A-005, …
-
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations …
-
Adicet Bio doses first subject in Phase I trial of renal cell carcinoma therapy
US-based biotechnology company Adicet Bio has dosed the first subject in a multicentre Phase I trial of ADI-270, a gamma …
-
Sorriso Pharma’s UC treatment hits Phase Ib endpoints
Utah biopharma company Sorriso Pharmaceuticals has confirmed its Phase Ib trial of an oral drug for patients with ulcerative colitis …
